Insmed Incorporated (NASDAQ:INSM) Insider Orlov S. Nicole Schaeffer Sells 91,140 Shares

Insmed Incorporated (NASDAQ:INSM) insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the transaction, the insider now owns 97,083 shares in the company, valued at $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Insmed Price Performance

Shares of INSM stock opened at $76.58 on Friday. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.63. The company has a market capitalization of $13.70 billion, a PE ratio of -13.80 and a beta of 1.12. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a fifty day simple moving average of $72.40 and a 200-day simple moving average of $72.98.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to the consensus estimate of $93.36 million. During the same period in the previous year, the company earned ($1.10) EPS. Insmed’s quarterly revenue was up 18.1% on a year-over-year basis. Equities research analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on INSM. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. Bank of America increased their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Truist Financial restated a “buy” rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $83.67.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently bought and sold shares of INSM. Geode Capital Management LLC raised its position in shares of Insmed by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock valued at $278,432,000 after purchasing an additional 172,664 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after acquiring an additional 214,130 shares in the last quarter. Vestal Point Capital LP boosted its stake in Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after acquiring an additional 850,000 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Insmed by 10.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,444,266 shares of the biopharmaceutical company’s stock worth $105,431,000 after acquiring an additional 137,670 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Insmed by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company’s stock worth $70,260,000 after purchasing an additional 24,025 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.